Crossbow Therapeutics, a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, announced it has raised $77 million in a Series B financing that will support the completion of the CROSSCHECK-001 Phase 1 clinical trial of the company's lead program, CBX-250, and accelerate development of additional T-Bolt™ immunotherapies designed to extend the reach of antibody therapy across a broad range of cancers.

This Series B financing was co-led by Taiho Ventures and Arkin Bio Capital, with participation from new investors Sixty Degree Capital, Hamilton Square Partners Management LP, LifeLink Ventures, Libbs Ventures, and Blood Cancer United's Therapy Acceleration Program® (TAP), as well as existing investors MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly and Company, and Mirae Asset Venture Investment.